MarketN-Isopropyltryptamine
Company Profile

N-Isopropyltryptamine

N-Isopropyltryptamine (NiPT) is a serotonin receptor agonist of the tryptamine family.

Use and effects
According to Alexander Shulgin, no active dose level of NiPT has yet been found in humans. ==Pharmacology==
Pharmacology
Pharmacodynamics NiPT acts as a potent full agonist of the serotonin 5-HT2A receptor, whereas it is inactive as an agonist of the serotonin 5-HT1A receptor. The drug is also a weak serotonin reuptake inhibitor. ==Chemistry==
Chemistry
Analogues Analogues of NiPT include N-methyltryptamine (NET), N-ethyltryptamine, N-sec-butyltryptamine (NsBT), N-tert-butyltryptamine (NtBT), and diisopropyltryptamine (DiPT), among others. 5-MeO-NiPT is likewise a serotonin receptor agonist. It is a potent full agonist or high-efficacy partial agonist of the serotonin 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT2C receptors. In contrast to 5-MeO-NMT and 5-MeO-NET, which are inactive in the test, 5-MeO-NiPT induces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and hence may be hallucinogenic in humans. 4-HO-NiPT is also a serotonin receptor agonist and produces the head-twitch response in rodents as well. ==Society and culture==
Society and culture
Legal status Canada NiPT is not a controlled substance in Canada as of 2025. ==See also==
tickerdossier.comtickerdossier.substack.com